BRPI0414186A - compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto - Google Patents

compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto

Info

Publication number
BRPI0414186A
BRPI0414186A BRPI0414186-5A BRPI0414186A BRPI0414186A BR PI0414186 A BRPI0414186 A BR PI0414186A BR PI0414186 A BRPI0414186 A BR PI0414186A BR PI0414186 A BRPI0414186 A BR PI0414186A
Authority
BR
Brazil
Prior art keywords
treating
preventing
compounds
methods
antagonizing
Prior art date
Application number
BRPI0414186-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Guoging Cao
Ana Maria Escribano
Maria Carmen Fernandez
Todd Fields
Douglas Linn Gernert
Christopher Lawrence Cioffi
Robert Jason Herr
Nathan Bryan Mantlo
Eva Maria Martin De La Nava
Ana Isabel Mateo Herranz
Daniel Ray Mayhugh
Xiaodong Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0414186A publication Critical patent/BRPI0414186A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D225/00Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI0414186-5A 2003-10-08 2004-10-07 compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto BRPI0414186A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50973603P 2003-10-08 2003-10-08
PCT/US2004/030907 WO2005037796A1 (en) 2003-10-08 2004-10-07 Compounds and methods for treating dyslipidemia

Publications (1)

Publication Number Publication Date
BRPI0414186A true BRPI0414186A (pt) 2006-10-31

Family

ID=34465112

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414186-5A BRPI0414186A (pt) 2003-10-08 2004-10-07 compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto

Country Status (25)

Country Link
US (1) US7749992B2 (enExample)
EP (2) EP2098512A1 (enExample)
JP (1) JP4773969B2 (enExample)
KR (1) KR20060085675A (enExample)
CN (1) CN1863778A (enExample)
AT (1) ATE442358T1 (enExample)
AU (1) AU2004282101A1 (enExample)
BR (1) BRPI0414186A (enExample)
CA (1) CA2537942A1 (enExample)
CY (1) CY1110537T1 (enExample)
DE (1) DE602004023100D1 (enExample)
DK (1) DK1670768T3 (enExample)
EA (1) EA200600737A1 (enExample)
EC (1) ECSP066484A (enExample)
ES (1) ES2332051T3 (enExample)
HR (1) HRP20090581T1 (enExample)
IL (1) IL173819A0 (enExample)
MA (1) MA28268A1 (enExample)
MX (1) MXPA06003927A (enExample)
NO (1) NO20062074L (enExample)
PL (1) PL1670768T3 (enExample)
PT (1) PT1670768E (enExample)
SI (1) SI1670768T1 (enExample)
WO (1) WO2005037796A1 (enExample)
ZA (1) ZA200602888B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470705B2 (en) * 2004-03-26 2008-12-30 Eli Lilly And Company Compounds and methods for treating dyslipidemia
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
US7652023B2 (en) * 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
CN103833636B (zh) * 2014-03-31 2015-09-02 武汉武药制药有限公司 一种莫扎伐普坦中间体的合成方法
CN108137508B (zh) * 2015-07-31 2021-08-27 艾尼纳制药公司 5-ht2c受体激动剂和组合物及使用方法
CN110291383B (zh) * 2017-02-23 2021-12-28 株式会社Ihi Oh自由基检测探测器、oh自由基测定装置以及oh自由基测定方法
CN113195475A (zh) 2018-10-24 2021-07-30 Viiv保健英国第五有限公司 人免疫缺陷病毒复制的抑制剂
MX2022012881A (es) 2020-04-15 2022-11-08 Viiv Healthcare Uk No 5 Ltd Inhibidores de replicacion del virus de inmunodeficiencia humana.
CN113636977B (zh) * 2021-09-01 2022-12-20 温州大学 2-芳基苯并氮杂卓及其衍生物的合成方法
CN117088814A (zh) * 2023-02-16 2023-11-21 烟台大学 一种三氟甲硫化氮杂-8/9元环化合物的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
TW270927B (enExample) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
HUT75160A (en) * 1994-03-24 1997-04-28 Merrell Pharma Inc Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic aminoacetylmercapto derivatives
WO1995034540A1 (en) * 1994-06-15 1995-12-21 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
JPH09214746A (ja) 1996-02-02 1997-08-15 Ricoh Co Ltd 画像出力システム及び画像形成装置
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6333349B1 (en) * 1997-02-26 2001-12-25 Aventis Pharma Deutschland Gmbh Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Fo−5637a物質及びb物質並びにそれらの製造法
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US6664522B2 (en) * 2000-03-30 2003-12-16 Homer L. Spencer Method and apparatus for sealing multiple casings for oil and gas wells
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
YU84303A (sh) * 2001-04-30 2006-05-25 Pfizer Products Inc. Postupak dobijanja cetp inhibitora
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
RU2004123637A (ru) 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового
ES2358898T3 (es) 2002-07-01 2011-05-16 Cytec Surface Specialties, S.A. Precursores de polímeros diluibles en agua, su preparación y su uso.
NZ532494A (en) * 2002-08-30 2006-03-31 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof
BR0315041A (pt) * 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
US20060100239A1 (en) 2003-03-04 2006-05-11 Izuru Nagasaki Method for producing optically active amines
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005033082A2 (en) 2003-09-30 2005-04-14 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
US7470705B2 (en) * 2004-03-26 2008-12-30 Eli Lilly And Company Compounds and methods for treating dyslipidemia
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法

Also Published As

Publication number Publication date
EP2098512A1 (en) 2009-09-09
AU2004282101A1 (en) 2005-04-28
DK1670768T3 (da) 2009-11-09
US7749992B2 (en) 2010-07-06
ZA200602888B (en) 2007-11-28
CA2537942A1 (en) 2005-04-28
PL1670768T3 (pl) 2010-01-29
PT1670768E (pt) 2009-11-20
CY1110537T1 (el) 2015-04-29
JP4773969B2 (ja) 2011-09-14
ECSP066484A (es) 2006-10-10
HRP20090581T1 (hr) 2009-12-31
ATE442358T1 (de) 2009-09-15
KR20060085675A (ko) 2006-07-27
EP1670768A1 (en) 2006-06-21
IL173819A0 (en) 2006-07-05
JP2007508301A (ja) 2007-04-05
MXPA06003927A (es) 2008-02-07
EP1670768B1 (en) 2009-09-09
EA200600737A1 (ru) 2006-10-27
WO2005037796A1 (en) 2005-04-28
CN1863778A (zh) 2006-11-15
SI1670768T1 (sl) 2010-01-29
MA28268A1 (fr) 2006-11-01
US20070254869A1 (en) 2007-11-01
ES2332051T3 (es) 2010-01-25
NO20062074L (no) 2006-05-08
DE602004023100D1 (de) 2009-10-22

Similar Documents

Publication Publication Date Title
NO20052802L (no) Pyrrolopyrimidinderivativer
DE602004017479D1 (de) Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
BRPI0414186A (pt) compostos, métodos de antagonizar a atividade de cetp, de tratar ou prevenir uma doença, de diminuir o colesterol ldl plasmático em um mamìmero, de tratar e/ou prevenir seqüelas patológicas, formulação farmacêutica, e, uso de um composto
NO20100827L (no) Glukocorticoid-mimetica, fremgangsmater for fremstilling av dem, farmasoytiske blandinger, og anvendelser derav
DE602004011330D1 (de) Imidazo- und thiazolopyridine als jak3-kinase-inhibitoren
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
ATE532772T1 (de) Piperazinderivate und deren verwendung als therapeutische mittel
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
ATE543819T1 (de) Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
BR0213660A (pt) Composto, composição farmacêutica e método para tratar pacientes
ATE450534T1 (de) Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung
WO2005030120A3 (en) Antiangiogenic agents
NO20055688L (no) Organiske forbindelser
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ATE418551T1 (de) Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2007067711A3 (en) Certain chemical entities, compositions, and methods for modulating trpv1
DE60324544D1 (de) Muskarin antagonisten
BRPI0408338A (pt) piperidinas substituìdas como novos inibidores de mdm2-p53
ATE406364T1 (de) Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
BR0208275A (pt) Composições farmacêuticas para tratamento de arteriosclerose
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel
BRPI0408423A (pt) composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]